In a NSCLC xenograft model, treatment with the anti-PD-L1 CAR-T, δ-TCRγδ-T or γ-TCRγδ-T cells generated from two different donors effectively suppressed tumor progression for up to 46 days after infusion (Fig. 3A and Supplementary Fig. 2). This evidence concerns the gene CD274 and neoplasm.